SCN1A rs10930201: Epilepsy Pharmacogenomics and Drug Response
The rs10930201 variant is a single nucleotide polymorphism located in an intronic region of the SCN1A gene on chromosome 2. SCN1A encodes the alpha subunit of the neuronal Nav1.1 voltage-gated sodium channel, which serves as a primary pharmacological target for several first-line antiepileptic medications. Pharmacogenomic research has evaluated rs10930201 for its potential associations with altered therapeutic dosing requirements and pharmacoresistance to drugs like carbamazepine and phenytoin, though findings across clinical cohorts show moderate and sometimes mixed evidence.
What each genotype means
Typical SCN1A variant profile
This genotype represents the major allele combination for this regulatory region. Research into this variant suggests it may influence how the brain's sodium channels respond to certain medications, though evidence remains moderate and context-dependent. Please discuss your medication history and any concerns regarding treatment response with your clinician or pharmacist.
This is the most common genotype globally, found in the majority of individuals across most ancestral populations.
Intermediate SCN1A variant profile
Carrying one copy of the minor allele may be associated with subtle differences in how your body processes specific sodium channel-blocking medications like carbamazepine or phenytoin. Clinical studies have observed mixed results regarding therapeutic dosing requirements, so this information should be used only as a guide for discussion with your healthcare provider.
This heterozygous genotype is common, appearing in a significant portion of the global population.
Minor allele SCN1A profile
This genotype contains two copies of the minor allele, which has been investigated in pharmacogenomic studies for potential associations with altered responses to certain antiepileptic drugs. Because the evidence is based on statistical associations in specific populations, it does not predict your individual clinical outcome. Always consult your doctor before making any changes to your prescribed medication regimen.
This genotype is less common than the others but is still observed at a notable frequency across diverse world ancestries.
Genetic Location and Molecular Biology
The rs10930201 polymorphism is an intronic variation situated within SCN1A on human chromosome 2q24.3. Unlike coding mutations that alter amino acid sequences, intronic variants like rs10930201 do not directly change the primary structure of the Nav1.1 sodium channel protein. Instead, non-coding single nucleotide polymorphisms within SCN1A often reside in regulatory regions or splicing control motifs. Researchers examine these variants to understand whether they alter pre-mRNA splicing efficiency, alternative exon usage (such as neonatal versus adult channel isoforms), or general transcriptional activity. Because voltage-gated sodium channels are tightly regulated in neural tissue, even minor variations in gene expression or alternative transcript ratios could theoretically affect cellular electrophysiology and downstream sensitivity to ion channel blockers.
Function of the SCN1A Gene
The SCN1A gene encodes the alpha subunit of Nav1.1, a voltage-gated sodium channel essential for generating and propagating action potentials across neurons in the central nervous system. It plays a particularly crucial role in parvalbumin-positive GABAergic inhibitory interneurons. Adequate Nav1.1 function helps maintain the delicate balance between neuronal excitation and inhibition throughout the brain. Disruption of Nav1.1 activity can lower the seizure threshold, leading to hypersynchronous neuronal firing. Due to its central position in neuronal excitability, Nav1.1 is both a locus for genetic epilepsy disorders and a direct molecular target for traditional anti-seizure medications (ASMs) such as carbamazepine, phenytoin, and lamotrigine, which act by stabilizing the inactivated state of sodium channels.
Pharmacogenomic Evidence and Drug Resistance
Pharmacogenomic investigations into SCN1A variants have explored whether common polymorphisms correlate with antiepileptic drug efficacy, maximum tolerated doses, or refractory epilepsy. While classical functional variants like rs3812718 (IVS5N+5 G>A) have been extensively studied, rs10930201 has been investigated as part of regional linkage disequilibrium blocks and regulatory haplotype studies. Published clinical cohorts evaluating voltage-gated sodium channel blockers have found moderate associations between certain intronic SCN1A genotypes and altered dosing thresholds or drug resistance. However, findings across studies remain heterogeneous: associations identified in specific cohorts often show reduced effect sizes or lack statistical significance in others. Factors such as co-prescribed medications, differing clinical definitions of drug resistance, and complex polygenic backgrounds contribute to the variability of these results.
Global Allele Frequencies and Ancestry Patterns
According to population genomics databases such as gnomAD and dbSNP, rs10930201 is a common variant globally, exhibiting a minor allele frequency typically between 0.40 and 0.50 across major reference populations. Because both the major and minor alleles are widely distributed across European, East Asian, South Asian, African, and American ancestral cohorts, carrying an alternate allele is biologically normal rather than rare. However, the precise degree of linkage disequilibrium between rs10930201 and neighboring functional SCN1A variants can vary significantly between geographic populations. This linkage structure variation can influence whether rs10930201 appears strongly correlated with antiepileptic drug outcomes in a given ethnic cohort, highlighting the importance of ancestry-adjusted genomic research.
Clinical Considerations and Practical Utility
Understanding your rs10930201 genotype provides educational insight into pharmacological research on sodium channel genetics, but it cannot be used in isolation to diagnose epilepsy or choose a therapeutic regimen. Clinical pharmacogenomic guidelines from major bodies like the Clinical Pharmacogenetics Implementation Consortium (CPIC) emphasize other high-penetrance genetic markers—such as HLA-B*15:02 and HLA-A*31:01 for carbamazepine toxicity, or CYP2C9 variants for phenytoin clearance—over intronic SCN1A markers for clinical decision-making. Patients taking anti-seizure medications should never adjust, reduce, or discontinue their prescribed therapy based on direct-to-consumer genetic data, as sudden medication changes carry significant risks of breakthrough seizures or status epilepticus. Any questions regarding drug efficacy, tolerability, or dosage adjustments must be discussed directly with a qualified neurologist or clinical pharmacist.
How common is this variant?
The rs10930201 polymorphism is common worldwide, with a global minor allele frequency ranging between approximately 0.40 and 0.50 across major continental ancestries.
Frequently asked questions
Does having the rs10930201 variant mean my epilepsy medication will fail?
No. The statistical associations identified between intronic SCN1A variants and antiepileptic drug response are moderate and do not guarantee drug failure. Many individuals with variant genotypes achieve excellent seizure control on standard dosages of carbamazepine or phenytoin.
Can testing for rs10930201 replace other genetic tests for carbamazepine safety?
No, it cannot. Standard clinical pharmacogenetic screening for carbamazepine focuses on HLA-B*15:02 and HLA-A*31:01 to prevent severe allergic skin reactions, while phenytoin dosing relies heavily on CYP2C9 metabolism. Testing for rs10930201 does not replace these clinically validated safety screenings.
What should I do if my genetic report shows a variant genotype for rs10930201?
You should not alter, stop, or change your medication dosing under any circumstances without medical supervision. If you have concerns about the efficacy or side effects of your anti-seizure medication, bring your results to your neurologist or clinical pharmacist for a comprehensive evaluation.
Why is the SCN1A gene so important in epilepsy treatment?
SCN1A provides instructions for building Nav1.1, a specialized voltage-gated sodium channel that regulates electrical firing in brain cells. Because medications like carbamazepine and phenytoin work by directly blocking these channels, genetic differences in SCN1A may alter how sensitive the channels are to treatment.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10930201?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN1A
A variant in the SCN1A gene that may influence the effective dosage and side-effect profile of phenytoin and other anti-epileptic drugs.
A missense variant (c.3184A>G, p.Thr1067Ala) widely assessed for responsiveness and dosage sensitivity to sodium-channel-blocking antiepileptic drugs such as carbamazepine and valproate.
This variant in the SCN1A gene influences sodium channel expression and has been associated with altered dose requirements and clinical response to anti-seizure medications including phenytoin and carbamazepine.